See the published version of this preprint at BMC Medical Imaging.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Bing Liu
Xijing Hospital Department of Radiology
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8821-5935
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose: To testify whether multi-b-values DWI can be used to ultra-early predict treatment response of CCRT in cervical cancer patients and to assess the predictive ability of concerning parameters. Methods: 53 patients with biopsy proved cervical cancer were retrospectively recruited in this study. All patients underwent pelvic multi-b-values DWI before and at the 3rd day during treatment. Tumor diffusion parameters were calculated by mono-exponential (apparent diffusion coefficient, ADC), bi-exponential (Dslow, Dfast and fp) and stretched exponential (distributed diffusion coefficient, DDC and α) models. Treatment response was assessed based on RECIST v1.1 at 1 month after the completion of whole CCRT. Parameters were compared using independent t test or Mann-Whitney U test as appropriate. Receiver operating characteristic (ROC) curves was used for statistical evaluations. Results: ADC-T0 (p=0.02), Dslow-T0 (p<0.01), DDC-T0 (p=0.03), ADC-T1 (p<0.01), Dslow-T1 (p<0.01), ΔADC (p=0.04) and Δα (p<0.01) were significant lower in non-CR group patients. ROC analyses showed that ADC-T1 and Δα exhibited high prediction value, with area under the curves of 0.880 and 0.869, respectively. Conclusion: Multi-b-values DWI can be used as a noninvasive technique to assess and predict treatment response in cervical cancer patients at the 3rd day of CCRT. ADC-T1 and Δα can be used to differentiate good responders from poor responders.
Keywords
Cervical cancer, Diffusion Magnetic Resonance Imaging, Concomitant Chemoradiotherapy
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Medical Imaging.
No community comments so far
Editorial decision: Accept
On 06 Aug, 2020
Editor assigned
On 05 Aug, 2020
Submission checks complete
On 04 Aug, 2020
Editor invited
On 04 Aug, 2020
No comments provided
Review #2 received
Received 25 Jul, 2020
Reviewer #2 agreed
On 14 May, 2020
Reviewer #1 agreed
On 12 May, 2020
Review #1 received
Received 12 May, 2020
Reviewers invited
Invitations sent on 11 May, 2020
Editor assigned
On 30 Apr, 2020
Editor invited
On 29 Apr, 2020
Submission checks complete
On 30 Dec, 2019
Version 1
Posted 02 Jan, 2020
No comments provided
Editorial decision: Major revision
On 21 Apr, 2020
Review #3 received
Received 16 Apr, 2020
Review #4 received
Received 16 Apr, 2020
Reviewer #4 agreed
On 14 Apr, 2020
Reviewer #3 agreed
On 12 Apr, 2020
Review #2 received
Received 30 Mar, 2020
Review #1 received
Received 29 Mar, 2020
Reviewer #2 agreed
On 19 Mar, 2020
Reviewer #1 agreed
On 12 Feb, 2020
Reviewers invited
Invitations sent on 14 Jan, 2020
Editor invited
On 30 Dec, 2019
Editor assigned
On 26 Dec, 2019
Submission checks complete
On 25 Dec, 2019
First submitted
On 24 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nuclear Medicine & Medical Imaging
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Medical Imaging.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Bing Liu
Xijing Hospital Department of Radiology
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8821-5935
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Medical Imaging.
No community comments so far
Editorial decision: Accept
On 06 Aug, 2020
Editor assigned
On 05 Aug, 2020
Submission checks complete
On 04 Aug, 2020
Editor invited
On 04 Aug, 2020
No comments provided
Review #2 received
Received 25 Jul, 2020
Reviewer #2 agreed
On 14 May, 2020
Reviewer #1 agreed
On 12 May, 2020
Review #1 received
Received 12 May, 2020
Reviewers invited
Invitations sent on 11 May, 2020
Editor assigned
On 30 Apr, 2020
Editor invited
On 29 Apr, 2020
Submission checks complete
On 30 Dec, 2019
Version 1
Posted 02 Jan, 2020
No comments provided
Editorial decision: Major revision
On 21 Apr, 2020
Review #3 received
Received 16 Apr, 2020
Review #4 received
Received 16 Apr, 2020
Reviewer #4 agreed
On 14 Apr, 2020
Reviewer #3 agreed
On 12 Apr, 2020
Review #2 received
Received 30 Mar, 2020
Review #1 received
Received 29 Mar, 2020
Reviewer #2 agreed
On 19 Mar, 2020
Reviewer #1 agreed
On 12 Feb, 2020
Reviewers invited
Invitations sent on 14 Jan, 2020
Editor invited
On 30 Dec, 2019
Editor assigned
On 26 Dec, 2019
Submission checks complete
On 25 Dec, 2019
First submitted
On 24 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nuclear Medicine & Medical Imaging
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Medical Imaging.
Purpose: To testify whether multi-b-values DWI can be used to ultra-early predict treatment response of CCRT in cervical cancer patients and to assess the predictive ability of concerning parameters. Methods: 53 patients with biopsy proved cervical cancer were retrospectively recruited in this study. All patients underwent pelvic multi-b-values DWI before and at the 3rd day during treatment. Tumor diffusion parameters were calculated by mono-exponential (apparent diffusion coefficient, ADC), bi-exponential (Dslow, Dfast and fp) and stretched exponential (distributed diffusion coefficient, DDC and α) models. Treatment response was assessed based on RECIST v1.1 at 1 month after the completion of whole CCRT. Parameters were compared using independent t test or Mann-Whitney U test as appropriate. Receiver operating characteristic (ROC) curves was used for statistical evaluations. Results: ADC-T0 (p=0.02), Dslow-T0 (p<0.01), DDC-T0 (p=0.03), ADC-T1 (p<0.01), Dslow-T1 (p<0.01), ΔADC (p=0.04) and Δα (p<0.01) were significant lower in non-CR group patients. ROC analyses showed that ADC-T1 and Δα exhibited high prediction value, with area under the curves of 0.880 and 0.869, respectively. Conclusion: Multi-b-values DWI can be used as a noninvasive technique to assess and predict treatment response in cervical cancer patients at the 3rd day of CCRT. ADC-T1 and Δα can be used to differentiate good responders from poor responders.
Figure 1
Figure 2
Figure 3
Loading...